AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors

被引:41
作者
Fassnacht, M [1 ]
Weismann, D
Ebert, S
Adam, P
Zink, M
Beuschlein, F
Hahner, S
Allolio, B
机构
[1] Univ Wurzburg, Dept Med, Endocrine & Diabet Unit, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Dept Internal Med 1, D-97080 Wurzburg, Germany
[3] Univ Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany
[4] Univ Freiburg, Endocrine & Diabet Unit, Dept Med 2, D-179106 Freiburg, Germany
关键词
D O I
10.1210/jc.2004-2198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Activation of AKT plays a major role in a variety of human neoplasias. In mice, a heterozygous deletion of the Pten gene is associated with increased activation of AKT and with development of pheochromocytomas. Objective: The objective of this study was the investigation of the role of AKT in the pathogenesis of pheochromocytomas and adrenocortical tumors. Design, Setting, and Participants: Total AKT and phosphorylated AKT (pAKT) in 15 pheochromocytomas, nine aldosterone-producing adenomas, nine cortisol-producing adenomas, eight adrenocortical carcinomas (ACC), and 15 normal adrenals were investigated by Western blot analysis. Immunohistochemistry for total AKT and pAKT was performed in pheochromocytomas (n = 8), ACC (n = 4), and normal adrenal glands (n = 2). In addition, in pheochromocytomas PTEN protein expression and PTEN loss of heterozygosity were analyzed. Main Outcome Measures: Determination of pAKT/total AKT ratio in adrenal tissues was the main outcome. Results: In comparison to normal adrenals, total AKT-expression was elevated in both pheochromocytomas (193 +/- 22%) and ACC (176 +/- 36%). The pAKT/AKT ratio was significantly increased in pheochromocytomas (338 +/- 49% vs. 100 +/- 11%) but not in ACC, aldosterone-producing adenomas, and cortisol-producing adenomas. No loss of heterozygosity of PTEN and no decrease in PTEN protein was detected in pheochromocytomas. Immunohistochemistry showed strong and homogeneous AKT and pAKT staining in pheochromocytomas and focal staining in ACC. Conclusion: Our findings provide evidence for increased activation of AKT in pheochromocytomas but not in adrenocortical adenomas.
引用
收藏
页码:4366 / 4370
页数:5
相关论文
共 42 条
[31]   AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells [J].
Sun, M ;
Wang, G ;
Paciga, JE ;
Feldman, RI ;
Yuan, ZQ ;
Ma, XL ;
Shelley, SA ;
Jove, R ;
Tsichlis, PN ;
Nicosia, SV ;
Cheng, JQ .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :431-437
[32]   Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer [J].
Terakawa, N ;
Kanamori, Y ;
Yoshida, S .
ENDOCRINE-RELATED CANCER, 2003, 10 (02) :203-208
[33]   PI3K/Akt signalling pathway and cancer [J].
Vara, JAF ;
Casado, E ;
de Castro, J ;
Cejas, P ;
Belda-Iniesta, C ;
González-Barón, M .
CANCER TREATMENT REVIEWS, 2004, 30 (02) :193-204
[34]   REGULATION BY GROWTH-FACTORS (IGF-I, B-FGF AND TGF-BETA) OF PROTOONCOGENE MESSENGER-RNA, GROWTH AND DIFFERENTIATION OF BOVINE ADRENOCORTICAL FASCICULATA CELLS [J].
VIARD, I ;
JAILLARD, C ;
SAEZ, JM .
FEBS LETTERS, 1993, 328 (1-2) :94-98
[35]   The phosphatidylinositol 3-kinase-AKT pathway in human cancer [J].
Vivanco, I ;
Sawyers, CL .
NATURE REVIEWS CANCER, 2002, 2 (07) :489-501
[36]   HIGH-FREQUENCY OF GERMLINE P53 MUTATIONS IN CHILDHOOD ADRENOCORTICAL CANCER [J].
WAGNER, J ;
PORTWINE, C ;
RABIN, K ;
LECLERC, JM ;
NAROD, SA ;
MALKIN, D .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (22) :1707-1710
[37]   Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression [J].
Whang, YE ;
Wu, XY ;
Suzuki, H ;
Reiter, RE ;
Tran, C ;
Vessella, RL ;
Said, JW ;
Isaacs, WB ;
Sawyers, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5246-5250
[38]   Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma [J].
Yamamoto, S ;
Tomita, Y ;
Hoshida, Y ;
Morooka, T ;
Nagano, H ;
Dono, K ;
Umeshita, K ;
Sakon, M ;
Ishikawa, O ;
Ohigashi, H ;
Nakamori, S ;
Monden, M ;
Aozasa, K .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2846-2850
[39]   Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice [J].
You, MJ ;
Castrillon, DH ;
Bastian, BC ;
O'Hagan, RC ;
Bosenberg, MW ;
Parsons, R ;
Chin, L ;
DePinho, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1455-1460
[40]   Epigenetic PTEN silencing in malignant melanomas without PTEN mutation [J].
Zhou, XP ;
Gimm, O ;
Hampel, H ;
Niemann, T ;
Walker, MJ ;
Eng, C .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (04) :1123-1128